Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Bai, Hua ^a   Wang, Zhijie ^a   Wang, Yuyan ^a   Zhuo, Minglei ^a   Zhou, Qinghua ^b   Duan, Jianchun ^a   Yang, Lu ^a   Wu, Meina ^a   An, Tongtong ^a   Zhao, Jun ^a   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DRUG EFFICACY; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC CORRELATION; GENETIC HETEROGENEITY; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICRODISSECTION; MUTATIONAL ANALYSIS; PROGRESSION FREE SURVIVAL; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84873887494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054170     Document Type: Article

References (31)

1. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311.
4. Sequist LV, Bell DW, Lynch TJ, Haber DA, (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25: 587-595.
5. Uramoto H, Mitsudomi T, (2007) Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 96: 857-863.
6. Wu K, House L, Liu W, Cho WC, (2012) Personalized targeted therapy for lung cancer. Int J Mol Sci 13(9): 11471-11496.
7. Na II, Kim HR, Lee JK, Park SH, Kim CH, et al. (2012) Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer. J Cancer Res Ther 8(3): 373-378.
8. Jänne PA, (2008) Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumors. Lung Cancer 60: s3-9.
9. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, et al. (2010) Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer. Clin Cancer Res 16: 5489-5498.
10. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
11. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, et al. (2008) Engelman. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest118(7): 2609-2619.
12. Magee JA, Piskounova E, Morrison SJ, (2012) Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty. Cancer Cell 21: 283-296.
13. Turner NC, Reis-Filho JS, (2012) Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13: e178-85.
14. Nowell P, (1986) Mechanisms of tumor progression. Cancer Res 46: 2203-2207.
15. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N Engl J Med 366(10): 883-892.
16. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, et al. (2011) Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma. Cancer Cell 20: 810-817.
17. Bai H, Wang ZhJ, Chen KN, Zhao J, Lee J, et al. (2012) Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 30: 3077-3083.
18. Yatabe Y, Matsuo K, Mitsudomi T, (2011) Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma. J Clin Oncol 29(22): 2972-2977.
19. Bai H, Mao L, Wang HS, Zhao J, Yang L, et al. (2009) Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer. J Clin Oncol 27(16): 2653-2659.
20. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655.
21. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y, (2001) The new World Health organization classification of lung tumours. Eur Respir J 18: 1059-1068.
22. Detterbeck FC, Boffa DJ, Tanoue LT, (2009) The New Lung Cancer Staging System. Chest 136: 260-271.
23. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, et al. (2012) EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol Nov 21. [Epub ahead of print].
24. Cohen V, Agulnik JS, Jarry J, Batist G, Small D, et al. (2006) Evaluation of Denaturing High-Performance Liquid Chromatography as a Rapid Detection Method for Identification of Epidermal Growth Factor Receptor mutations in Non-small-Cell Lung Cancer. Cancer 107: 2858-2865.
25. Chin TM, Anuar D, Soo R, Salto-Tellez M, Li WQ, et al. (2007) Detection of Epidermal Growth Factor Receptor Variations by Partially Denaturing HPLC. Clin Chemistry53(1): 62-70.
26. Pühringer-Oppermann FA, Stein HJ, Sarbia M, (2007) Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Dis Esophagus 20: 9-11.
27. Gonzalez-Garcia I, Sole RV, Costa J, (2002) Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci USA 99: 13085-13089.
28. Lichy JH, Dalbègue F, Zavar M, Washington C, Tsai MM, et al. (2000) Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest 80: 291-301.
29. Diaz-Cano SJ, Blanes A, Rubio J, Matilla A, Wolfe HJ, (2000) Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder. Lab Invest 80: 279-289.
30. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, et al. (1998) Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 90: 233-237.
31. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K, (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99(5): 929-935.